ISSN: 2161-1017
Endocrinology & Metabolic Syndrome
Like us on:
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
 
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Regucalcin may be a Target Molecule in Diabetes

Masayoshi Yamaguchi*
Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, USA
Corresponding Author : Masayoshi Yamaguchi
Division of Diabetes, Endocrinology and Metabolism
Department of Medicine
Baylor College of Medicine
One Baylor Plaza, Houston
TX 77030, USA
E-mail: yamamasa1155@yahoo.co.jp
Received August 07, 2012; Accepted August 07, 2012; Published August 10, 2012
Citation: Yamaguchi M (2012) Regucalcin may be a Target Molecule in Diabetes. Endocrinol Metab Synd 1:e112. doi:10.4172/2161-1017.1000e112
Copyright: © 2012 Yamaguchi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Endocrinology & Metabolic Syndrome

Regucalcin was discovered in 1978 as a unique calcium-binding protein that does not contain EF-hand motif of calcium-binding domain [1-3]. The name regucalcin, which was proposed for this calcium-binding protein, suppresses calcium signaling that mediates many intracellular responses, which are amplified through calmodulin and protein kinase C [2,4]. The regucalcin gene, which consists of seven exons and six introns, is localized on the X chromosome and is identified in over 15 species consisting of regucalcin (RGN) family [5]. The protein named as senescene marker protein-30 (SMP30), which is identical to regucalcin, is also reported after discovery of regucalcin [6]. Regucalcin has been demonstrated to play a multifunctional role in the regulation in many tissues and cell types [7-12]. Regucalcin plays a pivotal role in maintaining of intracellular Ca2+ homeostasis and as a suppressor protein in various signal transductions in maintaining of cell homeostasis for stimuli. Moreover, regucalcin, which is localized into the nucleus, has been shown to suppress protein kinase and protein phosphatase activities, Ca2+-activated deoxyribonucleic acid (DNA) fragmentation, and DNA and ribonucleic acid (RNA) synthesis in the nucleus of many cell types. Regucalcin has also been shown to suppress protein synthesis and activate proteolysis, suggesting a role in protein turnover. Overexpression of endogenous regucalcin has been demonstrated to suppress cell proliferation and apoptosis, which is mediated through various signal factors, in the cloned rat hepatoma H4-II-E cells and normal rat kidney tubular epithelial NRK52E cells.
There is growing evidence that regucalcin may be a key molecule in metabolic disorder including diabetes and lipid metabolism. Insulin has been shown to stimulate the regucalcin gene expression in the liver cells. The hepatic regucalcin mRNA level is reduced after fasting of overnight about 70% of that in feeding rats [13]. Re-feeding produces a remarkable elevation of hepatic regucalcin mRNA and protein levels [13]. Oral administration of glucose to fasted rats caused a significant increase in hepatic regucalcin mRNA levels [13], suggesting an involvement of insulin secreted from pancreatic cells after glucose administration. Moreover, hepatic regucalcin mRNA level was clearly elevated after a single subcutaneous administration of insulin to fasted rats [13]. These findings suggest that hepatic regucalcin mRNA expression stimulated by re-feeding is involved in the action of insulin as its stimulating factors. Insulin has also been shown to directly stimulate regucalcin mRNA and protein levels by using the cloned human hepatoma cells (HepG2) in vitro [14]. Thus, insulin stimulates regucalcin expression in liver cells. Regucalcin may play a role in cellular regulation that is related to insulin action in liver cells.
Hepatic regucalcin levels have been shown to decrease about 50% of control levels at 1 or 3 weeks after a single subcutaneous administration of streptozotocin (STZ) which induces type-I diabetic state [15], suggesting an involvement of regucalcin in diabetes. The decrease in hepatic regucalcin may lead to the disorder of liver metabolism in diabetic state.
Deficiency of regucalcin has been demonstrated to induce an impairment of glucose tolerance by using regucalcin knockout (KO) mice treated with L-ascorbic acid because deficiency of regucalcin induces a decrease in serum vitamin C [16,17]. Blood glucose levels in regucalcin KO mice were increased by 25% at 30 min after glucose administration compared with wild-type mice [17]. Serum insulin levels in the KO mice were decreased by 37% at 30 min after glucose compared with wild-type mice [17]. Interestingly, an insulin tolerance test shows a greater glucose-lowering effect in regucalcin KO mice [17], suggesting that the KO mice reveal enhanced insulin sensitivity regardless of vitamin C status [18]. Moreover, high-fat diet feeding severely worsened glucose tolerance in both wild type and regucalcin KO mice [17].
Insulin resistance may be modeled in the cloned rat hepatoma H4- II-E cells in tissue culture with the use of the cytokine tumor necrosis factor-alpha (TNF-α) and insulin [18]. This tissue-culture model nicely mimics insulin resistance in human type 2 diabetic mellitus. H4-II-E cells were cultured with insulin alone, TNF-α alone, and TNF-α plus insulin, as well as a control sample [18]. From the proteome analysis of H4-II-E cells exposed to insulin and TNF-α, regucalcin is identified as a protein which is involved in insulin resistance, although it is identified other 13 proteins including regulators of translation, protein degradation, cellular Ca2+ signaling, G-proteins, and free-radical production [18]. Regucalcin, which is known to be a regulatory protein in Ca2+-dependent signaling pathway [7-9], is a molecule that is related to insulin resistance.
The role of regucalcin in the regulation of glucose utilization and lipid production is shown using the modeled H4-II-E cells overexpressing endogenous regucalcin (transfectants) in vitro [19]. Overexpression of regucalcin stimulates the production of triglyceride and free fatty acid in H4-II-E cells cultured with or without the supplementation of glucose in the absence of insulin [19], suggesting that regucalcin may stimulate lipid production, which is linked to glucose metabolism in the cells in vitro. Interestingly, the effect of insulin, which enhances medium glucose consumption, triglyceride and free fatty acid productions in wild-type cells cultured with glucose supplementation, is found to repress in the transfectants overexpressing regucalcin [20].
The expression of acetyl-CoA carboxylase, HMG-CoA reductase, glucokinase and pyruvate kinase mRNAs is not changed in wildtype cells and transfectants after culture with or without glucose supplementation in the presence of insulin [20], suggesting that regucalcin does not have a stimulatory effect on the gene expression of enzymes, which are related to glucose and lipid metabolism. It is possible; however, that regucalcin has a regulatory effect on various enzyme activities, which are related to glucose and lipid metabolism in liver cells.
Overexpression of regucalcin is found to have a suppressive effect on the expression of rat Insulin receptor (Insr) or phosphatidylinositol 3-kinase (PI3K) mRNAs enhanced after culture with glucose supplementation in the presence of insulin, although it did not have a significant effect on Insr and PI3K mRNAs expression in the cells cultured in the absence of insulin [20]. Endogenous regucalcin may suppress the gene expression of insulin signaling-related proteins. The suppressive effect of regucalcin on Insr and PI3K mRNAs expression may be important in causing of insulin resistance in H4-II-E cells overexpressing endogenous regucalcin. Insulin resistance in the liver is associated with the pathogenesis of nonalcoholic fatty liver disease.
Regucalcin has been shown to have a regulatory effect on lipid metabolism. Hepatocytes from regucalcin KO mice but not the wildtype mice at 12 months of age have been shown to contain many lipid droplets, abnormally enlarged mitochondria with indistinct cristae, and enlarged lysosomes filled with electron-dense bodies in the electron microscope [21]. Biochemical analysis of neutral lipids, total hepatic triglyceride, and cholesterol from regucalcin KO mice showed approximately 3.6- and 3.3-fold higher levels, respectively, than those from age-matched wild-type mice [21]. Moreover, values for total hepatic phospholipids from regucalcin KO mice were approximately 3.7-fold higher than those for their wild-type counterparts.
Regucalcin transgenic (TG) rats with overexpression of endogenous regucalcin have been shown to induce a remarkable of bone loss associated with increase in serum triglyceride and high-density lipoprotein (HDL)-cholesterol concentrations at the age of 36 weeks in vivo [22]. Serum free fatty acid, triglyceride, cholesterol or HDLcholesterol concentrations were markedly increased in regucalcin TG male and female rats at 14-50 weeks of age [22]. Hyperlipidemia is uniquely induced in regucalcin TG rats with increasing age. Moreover, the change in lipid components in the adipose and liver tissues of regucalcin TG rats with increasing age is shown in vivo [23]. Regucalcin is expressed in the adipose tissues of normal rats [23]. Triglyceride content in the adipose tissues is increased in 50-week-old regucalcin TG rats [23]. This increase may partly contribute hyperlipidemia.
Triglyceride, total cholesterol, or free fatty acid content in the liver tissues is decreased in 50-week-old regucalcin TG rats [23]. Liver glycogen content is decreased in the TG rats [23]. The expression of regucalcin in the liver tissues is enhanced in regucalcin TG rats [23]. Regucalcin has been shown to have a suppressive effect on the activations of glycogen particulate phosphorylase a, cytoplasmic pyruvate kinase, and fructose 1,6-diphosphatase by Ca2+ and calmodulin in rat liver [4,8,9]. Regucalcin may suppress glycogen synthesisin the liver and stimulate glycogenolysis in regucalcin TG rats. As the result, lipid synthesis may be stimulated in the liver tissues of the TG rats in vivo.
Leptin and adiponectine are adipokines that are involved in lipid metabolism [24,25]. Leptin mRNA expression in the adipose or liver tissues is found to decrease in 50-week-old regucalcin TG rats [23]. Adiponectin mRNA expression was not changed in the adipose tissues of the TG rats, while the levels were decreased in the liver tissues [23]. These decreases may be partly involved in hyperlipidemia induced in regucalcin TG rats. Thus, regucalcin may play an important role in the disorder of lipid metabolism in the liver.
Hyperlipidemia has been shown to induce in the lipoprotein lipasedeficient mice [26], low-density lipoprotein (LDL) receptor-deficient mice [27], apolipoprotein C3-KO mice [28], apolipoprotein C1 TG mice [29], very LDL lipoprotein receptor KO mice [30], cholesterol 7 alpha-hydroxylase-deficient mice [31], apoE-deficient mice [32], and hepatic myr-Akt overexpressing mice [33]. These animal models for hyperlipidemia are involved in molecules that regulate lipid metabolism. Regucalcin has also been proposed to be a key molecule that regulates lipid metabolism.
As described above, regucalcin plays a pathophysiological role in diabetes and lipid metabolism. Regucalcin, which is stimulated by insulin, is identified as a molecule that is related to insulin resistance in liver cells. Deficiency of regucalcin impaires glucose tolerance and induces lipid accumulation in the liver of mice in vivo [21]. Overexpression of regucalcin reveals a suppression of glycogen content and lipid components in the liver tissues of rats in vivo [23]. Moreover, hyperlipidemia is induced in regucalcin TG rats in vivo [22]. Regucalcin may be a key molecule in diabetes and lipid metabolic disorder in vivo. Thus, regucalcin may be important as a novel protein molecule in the understanding of pathophysiology in diabetes and lipid metabolic disorder. Regucalcin may be a target molecule for therapy of these diseases. Development of further study is expected.
 
References


































Select your language of interest to view the total content in your interested language
 
Share This Article
   
 
   
 
Relevant Topics
Disc Adrenal Disorders
Disc Advanced Type 1 Diabetes Treatment
Disc Advanced Type 2 Diabetes Treatment
Disc Advances in Steroids Detection
Disc Advances in Steroids Treatment
Disc Advances of Diabetes Cure
Disc Anabolic Steroids
Disc Appetite
Disc Basal Metabolic Rate
Disc Behavioral Endocrinology
Disc Belly Fat
Disc Calcium Homeostasis
Disc Catabolic Steroids
Disc Cellular Endocrinology
Disc Childhood Diabetes
Disc Comparative Endocrinology
Disc Complications of Hyperglycemia
Disc Complications of Hypoglycemia
Disc Cortico Steroids
Disc Cortisol
Disc Diabetes
Disc Diabetes Cholestrol
Disc Diabetes Lipid Metabolism
Disc Diabetes Statistics
Disc Diabetes and Alcohol
Disc Diabetes and Weight Loss
Disc Diabetes for Dummies
Disc Endocrine Oncology
Disc Endocrine System Diseases
Disc Endocrinologist
Disc Endocrinologist Communication
Disc Endocrinology
Disc Endocrinology Case Reports
Disc Epidural Steroids
Disc Female Steroids
Disc Goiter
Disc Graves Disease
Disc Graves’ Disease
Disc Gyno Steroids
Disc Hashimoto's Thyroiditis
Disc Hormonal Disorders
Disc Hormonal Imbalance
Disc Hormonal Therapy
Disc Hormone Epinephrine
Disc Hydrocortisone
Disc Hyperthyroidism
Disc Hyperthyroidism Symptoms
Disc Hypothyroidism
Disc Hypothyroidism Symptoms
Disc Illegal Steroids
Disc Infertility
Disc Insulin Resistance
Disc Iodine Deficiency
Disc Iodine Supplements
Disc Latest Research on Diabetes
Disc Levothyroxine
Disc Liquid Steroids
Disc Menopause
Disc Metabolic Acidosis
Disc Metabolic Disorder
Disc Metabolic Nutrition
Disc Metabolic Pathway
Disc Metabolic Syndrome
Disc Metabolic Syndrome Diet
Disc Metabolic Weight Loss
Disc Metabolism
Disc Metabolism Boosters
Disc Nasal Steroids
Disc Neuro-Endocrinology
Disc Neuroactive steroids
Disc Obesity and Diabetes
Disc Oral Steroids
Disc Paediatric Endocrinology
Disc Parathyroid
Disc Parathyroid Hormone
Disc Pathophysiology of Diabetes
Disc Reverse Diabetes
Disc Sex Hormone
Disc Steroid Myopathy
Disc Steroid Transformation
Disc Steroids Addiction
Disc Steroids Supplements
Disc Steroids and Alcohol
Disc Steroids in Pregnancy
Disc Syndrome X
Disc Synthetic Steroids
Disc TSH Levels
Disc TSH Test
Disc Thyroid Cancer
Disc Thyroid Gland
Disc Thyroid Nodules
Disc Thyroid Symptoms
Disc Thyroid Test
Disc Thyroid Treatment
Disc Thyroidectomy
Disc Thyrotoxicosis
Disc Thyroxine
Disc Type 1 Diabetes
Disc Type 2 Diabetes
Disc Veterinary Steroids
 
Recommended Journals
Disc Journal of Diabetes & Metabolism
Disc Journal of Thyroid Disorders & Therapy
Disc Journal of Metabolic Syndrome
Disc Journal of Steroids & Hormonal Science
  View More»
 
Recommended Conferences
Disc  2nd World Congress on Polycystic Ovarian Syndrome
October 05-07, 2016 Orlando, USA
 
Article Tools
Disc Export citation
Disc Share/Blog this article
 
Article usage
  Total views: 11158
  [From(publication date):
June-2012 - Jun 30, 2016]
  Breakdown by view type
  HTML page views : 7427
  PDF downloads :3731
 
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

 
OMICS International Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
 
 
OMICS International Conferences 2016-17
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings
 
 

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

agrifoodaquavet@omicsinc.com

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

clinical_biochem@omicsinc.com

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

business@omicsinc.com

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

chemicaleng_chemistry@omicsinc.com

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

environmentalsci@omicsinc.com

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

engineering@omicsinc.com

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

generalsci_healthcare@omicsinc.com

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

genetics_molbio@omicsinc.com

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

immuno_microbio@omicsinc.com

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

omics@omicsinc.com

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

materialsci@omicsinc.com

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

mathematics_physics@omicsinc.com

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

medical@omicsinc.com

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

neuro_psychology@omicsinc.com

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

pharma@omicsinc.com

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

social_politicalsci@omicsinc.com

1-702-714-7001 Extn: 9042

 
© 2008-2016 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version